BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biocon's subsidiary Biocon Biologics has received US FDA approval for Kirsty™ (Insulin Aspart-xjhz), making it the first and only interchangeable rapid-acting Insulin Aspart biosimilar approved in the United States. The product is a biosimilar to NovoLog® and is approved for adults and pediatric patients with diabetes, available in prefilled pen and vial forms. Kirsty has already been sold in Europe and Canada since 2022. The US Insulin Aspart market was worth approximately $1.9 billion in 2024 (IQVIA), with 38.4 million Americans living with diabetes. This expands Biocon Biologics' interchangeable biosimilar insulin portfolio, which already includes Semglee® (Insulin Glargine).
This approval opens a large $1.9 billion US market opportunity for Biocon Biologics and strengthens its position as a leading global biosimilar insulin player. For Biocon shareholders, the news is positive as it validates the company's R&D pipeline, adds a high-value revenue stream, and reinforces the long-term growth story of its biosimilars subsidiary.